Biotech Values

[postmeridiem]

I think one problem with ENTA's stock price is that the Credit Suisse analyst thinks ABBV is only going to sell $800 million dollars worth of V-Paks in 2016, and less every year after.

Can anyone contact Ravi Mehrotra to ask why he thinks sales will fall off a cliff next year, when ABBV has projected sales of $250 million per month by December 2015?